Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Upcoming results date; no new financials or clinical data disclosed.

What the company is saying

Cellectar Biosciences, Inc. is announcing it will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time. The announcement outlines the company's focus on developing proprietary cancer drugs using its Phospholipid Drug Conjugate platform. It highlights iopofosine I 131 as the lead asset, detailing its progress through Phase 2b trials for several cancer indications and ongoing evaluation in pediatric gliomas. The company emphasizes multiple regulatory designations from the FDA and EMA, including Breakthrough, Orphan Drug, Rare Pediatric Drug, Fast Track, and PRIME status for iopofosine I 131. Additional pipeline assets, CLR 125 and CLR 225, are described with reference to preclinical and early clinical development, but without quantitative results. The tone is factual and neutral, focusing on pipeline breadth and regulatory milestones rather than financial or commercial achievements.

What the data suggests

No financial figures, revenue, or expense data are disclosed in this announcement. The only numerical information relates to clinical trial phases and regulatory designations: iopofosine I 131 has completed Phase 2b trials in multiple indications and is in a Phase 1b study for pediatric gliomas, with six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations from the FDA, plus PRIME designation from the EMA. CLR 125 is in a Phase 1b study for triple negative breast cancer, but no enrollment, efficacy, or safety data are provided. CLR 225 and other preclinical programs are mentioned without supporting data. There is no evidence of recent business developments, financial performance, or operational milestones. The data quality is poor for financial analysis, as no numbers relevant to valuation or cash runway are included.

Analysis

The announcement is primarily a notice of an upcoming financial results release and corporate update, with a summary of the company's clinical pipeline and regulatory designations. There are no realised financial or operational milestones disclosed, nor are there any forward-looking projections of revenue, profitability, or timelines for product commercialisation. Most claims are factual statements about ongoing clinical trials, regulatory designations, and the existence of a product pipeline. The language is descriptive rather than promotional, and there are no exaggerated claims of imminent success or financial impact. No large capital outlay or immediate earnings impact is discussed. The gap between narrative and evidence is minimal, as the text avoids making unsupported or aspirational claims.

Risk flags

• ●Disclosure risk is high because no financial data, cash position, or operational milestones are included, leaving investors without information to assess near-term viability or capital needs.
• ●Execution risk is significant, as the lead asset iopofosine I 131 remains in clinical development with no disclosed timelines for regulatory approval or commercialization, and other pipeline assets are at even earlier stages.
• ●Pipeline risk exists because claims of efficacy, safety, and clinical progress for CLR 125 and CLR 225 are qualitative and unsupported by numerical or peer-reviewed data, making it difficult to gauge the likelihood of future success.

Bottom line

This announcement is a scheduling notice for Cellectar Biosciences' upcoming financial results and corporate update, not a disclosure of new financial or clinical data. Investors receive a summary of the pipeline and regulatory designations, but no information on cash, revenue, or trial outcomes. The lack of quantitative disclosure increases uncertainty about the company's financial health and operational progress. All product candidates remain in development, with no near-term catalysts or commercial milestones identified. The most actionable point is the August 13, 2026, date for potential new information. Until then, there is no basis for a change in investment view or valuation.

Announcement summary

(NASDAQ:CLRB) Cellectar Biosciences, Inc. announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time. The company’s product pipeline includes iopofosine I 131, which has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), relapsed or refractory multiple myeloma (MM), and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation. Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC. CLR 125 has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth and has been well tolerated in vivo. The company is also developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

Disagree with this article?